STOCK TITAN

Vertex (VRTX) director receives options, defers vested shares into stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vertex Pharmaceuticals director Suketu Upadhyay reported routine equity compensation and a related share deferral. Upon vesting of previously granted restricted stock units, he exchanged 796 shares of common stock for 796 deferred stock units under the company’s deferred compensation plan, recording a disposition to the issuer and a matching derivative acquisition.

He also received a grant of 2,866 stock options exercisable at $424.45 per share, expiring on April 30, 2036. Following these transactions, he holds 1,558 shares of common stock, 3,595.156 deferred stock units, and 2,866 stock options, all reported as direct ownership.

Positive

  • None.

Negative

  • None.
Insider Upadhyay Suketu
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,866 $0.00 --
Grant/Award Deferred Stock Units 796 $0.00 --
Disposition Common Stock 796 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 2,866 shares (Direct, null); Deferred Stock Units — 3,595.156 shares (Direct, null); Common Stock — 1,558 shares (Direct, null)
Footnotes (1)
  1. Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units. Fully vested. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.
Common shares disposed to issuer 796 shares Exchange for 796 deferred stock units on May 1, 2026
Deferred stock units granted 796 units One unit represents one share of common stock
Stock options granted 2,866 options Grant on May 1, 2026, fully vested
Option exercise price $424.45 per share Stock Option (Right to Buy) underlying common stock
Option expiration date April 30, 2036 Expiration of 2,866 stock options
Common shares after transactions 1,558 shares Directly held common stock following Form 4 entries
Deferred stock units after transactions 3,595.156 units Balance of deferred stock units after 796-unit grant
Stock options after transactions 2,866 options Total options reported as directly owned
Deferred Stock Units financial
"received instead 796 deferred stock units pursuant to our deferred compensation plan"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... underlying security title: Common Stock"
deferred compensation plan financial
"received instead 796 deferred stock units pursuant to our deferred compensation plan"
A deferred compensation plan is an arrangement where an employer agrees to pay part of an employee’s pay or bonus at a later date instead of immediately, often to reduce current tax bills or to tie rewards to long-term performance. For investors it matters because these promises create future cash obligations and influence executive incentives and retention; they can affect a company’s reported liabilities, cash flow planning and the risk profile if the business faces financial trouble.
change of control financial
"upon the earliest to occur of (i) termination ... (ii) a change of control of our company"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Upadhyay Suketu

(Last)(First)(Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026D796D(1)1,558D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$424.4505/01/2026A2,866 (2)04/30/2036Common Stock2,866$02,866D
Deferred Stock Units(3)05/01/2026A796 (3) (3)Common Stock796(1)3,595.156D
Explanation of Responses:
1. Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
2. Fully vested.
3. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.
Remarks:
/s/ Christiana Stevenson, Attorney-in-Fact05/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Vertex (VRTX) director Suketu Upadhyay report?

Suketu Upadhyay reported exchanging 796 shares of Vertex common stock for 796 deferred stock units and receiving 2,866 stock options. These are compensation and deferral-related entries, not open-market purchases or sales of shares.

Did Suketu Upadhyay buy or sell Vertex (VRTX) shares on the open market?

No open-market trades were reported. He recorded a disposition of 796 common shares back to the issuer in exchange for 796 deferred stock units under a deferred compensation plan, plus grants of deferred units and stock options.

How many Vertex (VRTX) stock options were granted to Suketu Upadhyay?

He received 2,866 stock options, each giving the right to buy one Vertex common share at an exercise price of $424.45. These options expire on April 30, 2036, and were reported as fully vested at grant.

What are the terms of Suketu Upadhyay’s deferred stock units in Vertex (VRTX)?

Each deferred stock unit equals one Vertex common share and will be paid in stock upon the earliest of his board service termination, a change of control of the company, or his disability or death, according to the plan description.

What are Suketu Upadhyay’s Vertex (VRTX) holdings after these Form 4 transactions?

After the reported transactions, he holds 1,558 shares of Vertex common stock directly, 3,595.156 deferred stock units, and 2,866 stock options. These positions reflect his reported equity exposure following the compensation and deferral entries.